Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nurix Therapeutics Inc (NRIX)

Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,295,479
  • Shares Outstanding, K 76,883
  • Annual Sales, $ 83,980 K
  • Annual Income, $ -264,460 K
  • EBIT $ -286 M
  • EBITDA $ -277 M
  • 60-Month Beta 1.96
  • Price/Sales 14.60
  • Price/Cash Flow N/A
  • Price/Book 2.28

Options Overview Details

View History
  • Implied Volatility 133.14% (-10.18%)
  • Historical Volatility 55.57%
  • IV Percentile 71%
  • IV Rank 25.56%
  • IV High 325.58% on 09/18/25
  • IV Low 67.05% on 02/07/25
  • Expected Move (DTE 13) 1.62 (9.58%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 28
  • Volume Avg (30-Day) 99
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 3,002
  • Open Int (30-Day) 3,156
  • Expected Range 15.24 to 18.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 02/28/26
See More
  • Average Estimate -0.76
  • Number of Estimates 6
  • High Estimate -0.67
  • Low Estimate -0.89
  • Prior Year -0.67
  • Growth Rate Est. (year over year) -13.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.87 +6.18%
on 02/05/26
20.18 -16.50%
on 01/22/26
-0.58 (-3.33%)
since 01/06/26
3-Month
11.67 +44.39%
on 11/07/25
22.50 -25.11%
on 12/08/25
+4.33 (+34.58%)
since 11/06/25
52-Week
8.18 +105.99%
on 04/10/25
22.50 -25.11%
on 12/08/25
-2.19 (-11.50%)
since 02/06/25

Most Recent Stories

More News
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class...

NRIX : 16.85 (+5.64%)
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic...

NRIX : 16.85 (+5.64%)
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

NRIX : 16.85 (+5.64%)
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median...

NRIX : 16.85 (+5.64%)
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH)...

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging...

NRIX : 16.85 (+5.64%)
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted...

NRIX : 16.85 (+5.64%)
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

SAN FRANCISCO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted...

NRIX : 16.85 (+5.64%)
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted...

NRIX : 16.85 (+5.64%)
Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies to treat cancer and...

NRIX : 16.85 (+5.64%)
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted...

NRIX : 16.85 (+5.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics...

See More

Key Turning Points

3rd Resistance Point 17.94
2nd Resistance Point 17.48
1st Resistance Point 17.17
Last Price 16.85
1st Support Level 16.40
2nd Support Level 15.94
3rd Support Level 15.63

See More

52-Week High 22.50
Fibonacci 61.8% 17.03
Last Price 16.85
Fibonacci 50% 15.34
Fibonacci 38.2% 13.65
52-Week Low 8.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar